Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
IRVINE, Calif., July 10, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP). Investors who purchased or otherwise acquired Neurotrope shares from January 7, 2016 through April 28, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 17, 2017 lead plaintiff motion deadline.
If you purchased Neurotrope shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Neurotrope made false and/or misleading statements and/or failed to disclose material adverse information about the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, the Company announced “positive top-line results” for the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer's disease.” The trial data refutes these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. After release of this news, the stock price of Neurotrope fell materially, which harmed investors according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
